ligufalimab (AK117) / Akesobio 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
15 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ligufalimab (AK117) / Akesobio
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Recruiting
3
510
RoW
AK117 in combination with AK112, Placebo in combination with Pembrolizumab
Akeso
Head and Neck Squamous Cell Carcinoma
01/27
10/27
AK112-206, NCT05382442: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Recruiting
2
254
US, RoW
AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil
Akeso, Summit Therapeutics
Metastatic Colorectal Cancer
05/26
08/28
AK117-203, NCT05227664: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Recruiting
2
120
RoW
AK117, AK112, Nab paclitaxel, paclitaxel
Akeso
Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer
07/25
12/26
AK117-205, NCT06196203: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Recruiting
2
90
US, RoW
AK117, Placebo, Azacitidine
Akeso
Higher-risk Myelodysplastic Syndromes
01/26
06/26
NCT06508606: AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC

Not yet recruiting
2
10
NA
AK117, anti-EGFR
West China Hospital
Head and Neck Squamous Cell Carcinoma
08/26
08/27
AK104-219, NCT05960955: Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
90
RoW
Cadonilimab, AK117, Oxaliplatin, Tegafur-gimeracil-oteracil potassium, Docetaxel, 5-Fluorouracil
Akeso
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
11/24
11/27
NCT06789848: Ligufalimab and Cadonilimab in Advanced Liver Cancers

Recruiting
2
64
US
Ligufalimab, Cadonilimab
University of Texas Southwestern Medical Center, Akesobio, Josephine Hughes Sterling Foundation
Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer
05/29
05/30
AK117-202, NCT05214482: A Study of AK112 in Advanced Malignant Tumors

Active, not recruiting
1/2
250
RoW
AK112, AK117, Chemotherapy
Akeso
Advanced Malignant Tumors
05/25
06/26
AK117-201, NCT05229497: A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Recruiting
1/2
114
RoW
AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil
Akeso
Advanced Malignant Tumors
02/23
02/24
AK117-204, NCT05235542: A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Recruiting
1/2
130
RoW
AK104, AK117, Capecitabine tablets, Oxaliplatin, Cisplatin, Paclitaxel, Irinotecan, Docetaxel, 5-FU
Akeso
Advanced Malignant Tumors
03/23
03/24
AK117-103, NCT04900350: A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

Active, not recruiting
1/2
136
RoW
AK117, Azacitidine
Akeso
Myelodysplastic Syndrome
09/25
12/25
AK117-104, NCT04980885: A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

Active, not recruiting
1/2
68
RoW
AK117, Azacitidine
Akeso
Acute Myeloid Leukemia
09/25
12/25
AK117-206, NCT06387420: A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

Not yet recruiting
1/2
180
RoW
AK117, Azacitidine, Venetoclax, Placebo
Akeso
ACUTE MYELOID LEUKEMIA; AML
04/26
04/27
NCT06642792: A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Recruiting
1/2
280
RoW
AK129, AK117
Akeso
Classic Hodgkin Lymphoma
11/27
02/28
AK117-102, NCT04728334: A Phase 1 Dose Escalation and Expansion Study of AK117

Completed
1
49
RoW
AK117
Akeso
Neoplasms Malignant
01/22
05/23

Download Options